Evotec initiate Phase I trial with P2X7 Antagonist « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
October 2008

M T W T F S S

« Sep Nov »

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

Evotec initiate Phase I trial with P2X7 Antagonist

Posted on October 14, 2008 by crimsoncanary

Evotec have initiated a Phase I clinical study of its proprietary, small molecule P2X7 receptor antagonist

Filed under: Uncategorized | Tagged: antagonist, Evotec, P2X7, phase I

« Neurogens aplindore effective in Phase II restless legs syndromw FDA approves AstraZeneca’s Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania »